8-K
filed January 6, 2023, 6:59 PM ET
ticker NWBO
CIK 0001072379
other material
confidence high
sentiment neutral
materiality 0.15
Northwest Biotherapeutics shareholders approve all six proposals at 2022 annual meeting
NORTHWEST BIOTHERAPEUTICS INC
- Re-elected directors Linda F. Powers and Navid Malik with 97.2% and 97.5% of votes cast respectively.
- Ratified Cherry Bekaert LLP as auditor for FY2022 with 98.8% of votes cast.
- Approved increase of authorized common shares from 1.2B to 1.7B with 95% of votes cast (73.8% of outstanding common).
- Approved advisory say-on-pay for 2021 executive compensation with 91.9% support.
- Ratified 2020 option awards to executives and independent directors with over 90% approval each.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC shareholders approved Approval of previously reported 2020 option awards to the Company's independent directors at the 2022-12-30 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-12-30
Exact text from the filing
The votes for approval were as follows: For Against Abstained Broker Non-Votes Approval of 2020 Option Awards to the Company's Independent Directors 619,934,754 (90.4%) 65,686,803 (9.6%) 8,392,803 (N/A) 147,209,551 (N/A)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC shareholders approved Election of Directors at the 2022-12-30 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-12-30
Exact text from the filing
The votes for Ms. Powers and Dr. Malik were as follows: For Withheld Broker Non-Votes Ms. Linda F. Powers 674,562,624 (97.2%) 19,451,736 (2.8%) 147,209,551 (N/A) Dr. Navid Malik 676,764,972 (97.5%) 17,249,388 (2.5%) 147,209,551 (N/A)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 1,200,000,000 to 1,700,000,000 at the 2022-12-30 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2022-12-30
Exact text from the filing
The votes for approval by the common and preferred stockholders, voting together as a single class, as a percentage of votes cast, and as a percentage of the total outstanding shares of Common and Preferred Stock combined as of the record date, were as follows: For Against Abstained Broker Non-Votes Common Stock Increase Amendment 799,877,480 37,214,287 4,132,144 0 Percent of votes cast (95.1%) (4.4%) (0.5%) Percent of total Common & Preferred Stock (74.3%) (3.5%) (0.4%)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC shareholders approved Ratification of Appointment of Cherry Bekaert LLP as the independent registered public accounting firm at the 2022-12-30 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2022-12-30
Exact text from the filing
The votes for appointment of Cherry Bekaert were as follows: For Against Abstained Broker Non-Votes Ratification of Cherry Bekaert LLP 829,094,918 (98.8%) 9,951,520 (1.2%) 2,177,473 (N/A) 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC shareholders approved Ratification of the same option awards made in 2020 to the Company's named executive officers at the 2022-12-30 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-12-30
Exact text from the filing
The votes for ratification were as follows: For Against Abstained Broker Non-Votes Ratification of Named Executive Officer Option Awards 613,009,482 (90.0%) 68,146,624 (10.0%) 12,858,254 (N/A) 147,209,551 (N/A)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NORTHWEST BIOTHERAPEUTICS INC shareholders approved Advisory vote on 2021 executive compensation at the 2022-12-30 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2022-12-30
Exact text from the filing
The votes for approval were as follows: For Against Abstained Broker Non-Votes Approval of 2021 Executive Compensation 625,747,069 (91.9%) 55,153,546 (8.1%) 13,113,745 (N/A) 147,209,551 (N/A)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.